Tommaso De Pas

Tommaso De Pas

UNVERIFIED PROFILE

Are you Tommaso De Pas?   Register this Author

Register author
Tommaso De Pas

Tommaso De Pas

Publications by authors named "Tommaso De Pas"

Are you Tommaso De Pas?   Register this Author

98Publications

2330Reads

37Profile Views

Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the Microbiome.

J Clin Oncol 2019 Feb 28;37(5):439. Epub 2018 Dec 28.

Laura Pala, MD; Luigi Nezi, PhD; Tommaso; De Pas, MD; Elisabetta Pennacchioli, MD; Emilia; Cocorocchio; Pierfrancesco Ferrucci, MD; Fabio; Conforti, MD; and Aron Goldhirsch, MD, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01270
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01270DOI Listing
February 2019

Sex as a predictor of response to cancer immunotherapy - Authors' reply.

Lancet Oncol 2018 08;19(8):e380-e381

Division of Medical Oncology for Melanoma & Sarcoma, European Institute of Oncology, Milan 20141, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30535-7DOI Listing
August 2018

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).

Lung Cancer 2018 06 9;120:27-33. Epub 2018 Mar 9.

Department of Oncology, University College London Cancer Institute, London, UK; University College London Hospitals NHS Foundation Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183029
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.03.007DOI Listing
June 2018

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.

Lancet Oncol 2018 06 16;19(6):737-746. Epub 2018 May 16.

Division of Medical Oncology for Melanoma & Sarcoma, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30261-4DOI Listing
June 2018

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

J Clin Oncol 2018 02 14;36(4):342-349. Epub 2017 Dec 14.

Paolo Andrea Zucali, Matteo Simonelli, Matteo Perrino, Fabio De Vincenzo, Laura Giordano, Monica Bertossi, Annarita Destro, Luca Di Tommaso, and Armando Santoro¸ Humanitas Clinical and Research Hospital; Tommaso De Pas, Francesca Toffalorio, Fabio Conforti, and Angela Cioffi, European Institute of Oncology; Paolo Andrea Zucali, Matteo Simonelli, Luca Di Tommaso, and Armando Santoro, Humanitas University, Milan; Giovannella Palmieri, Vincenzo Damiano, Margaret Ottaviano, and Sabino De Placido, Università Federico II, Naples; Adolfo Favaretto and Giulia Pasello, Istituto Oncologico Veneto, Padua; Antonio Chella and Erika Garbella, University Hospital, Pisa; Marcello Tiseo, Azienda Ospedaliero-Universitaria of Parma, Parma; and Michele Caruso and Marco Ali, Humanitas Centro Catanese di Oncologia, Catania, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.4078DOI Listing
February 2018

Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.

Future Oncol 2017 Dec 11;13(29):2629-2644. Epub 2017 Sep 11.

Medical Oncology of Melanoma & Sarcoma Unit, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0262DOI Listing
December 2017

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Cancer Treat Rev 2017 Apr 30;55:181-189. Epub 2017 Mar 30.

University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.006DOI Listing
April 2017

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 12 31;34(34):4079-4085. Epub 2016 Oct 31.

Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Alice T. Shaw, Massachusetts General Hospital; Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; D. Ross Camidge, University of Colorado Cancer Center, Denver, CO; Alberto Chiappori, Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Sai-Hong Ignatius Ou, University of California at Irvine, Orange, CA; Luigi De Petris, Karolinska Institutet, Stockholm, Sweden; Dong-Wan Kim, Seoul National University Hospital, Seoul; Ji-Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea; Denis L. Moro-Sibilot, Service de Pneumologie; Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble; Eric Dansin, Centre Oscar Lambret, Lille, France; Lucio Crino, Santa Maria della Misericordia Hospital, Perugia; Tommaso De Pas, European Institute of Oncology, Milan, Italy; Antje Tessmer, Evangelische Lungenklinik Berlin, Berlin, Germany; James Chih-Hsin Yang, Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University, Taipei, Taiwan; and Walter Bordogna, Sophie Golding, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4639DOI Listing
December 2016

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.

PLoS One 2014 19;9(8):e103883. Epub 2014 Aug 19.

Center of Predictive Molecular Medicine, Center of Excellence on Aging, University-Foundation, Chieti, Italy; Oncological and Cardiovascular Molecular Medicine Unit, Center of Excellence on Aging, University-Foundation, Chieti, Italy.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103883PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138040PMC
October 2015

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.

J Thorac Oncol 2015 Oct;10(10):1437-43

*Center of Predictive Molecular Medicine, Ce.S.I., G. D'Annunzio University-Foundation, Chieti, Italy; †Medical Scientific Affairs Department, Roche Molecular Systems, Pleasanton, California; ‡Oncological and Cardiovascular Molecular Medicine Unit, Ce.S.I., G. D'Annunzio University-Foundation, Chieti, Italy; §Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy; ‖Department of Medical Oncology, S. Maria della Misericordia Hospital, Perugia, Italy; ¶Department of Medical Oncology, Bellaria-Maggiore Hospital, Azienda USL of Bologna, Bologna, Italy; #Unit of Pneumology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; **Ospedale Civile di Pescara, Pescara, Italy; ††Ospedale Civile di Sulmona, Sulmona, Italy; ‡‡Department of Medical Oncology, Consorzio Interuniversitario Nazionale per la Bio-Oncologia, G. d'Annunzio University, Chieti, Italy; §§Department of Oncology-Haematology, Humanitas Cancer Center, IRCCS, Milan, Italy; and ‖‖Perugia University Medical School, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000643DOI Listing
October 2015

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.

J Thorac Oncol 2015 Oct;10(10):1458-67

*Thoracic Oncology Unit, Arnaud de Villeneuve Hospital/CHRU Montpellier, Montpellier, France; †Department of Pneumology, University Hospital, KU Leuven, Leuven, Belgium; ‡Medical Oncology, European Institute of Oncology, Milan, Italy; §Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah; ¶Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany; ‖Department of Respiratory Medicine, Ziekenhuis Oost Limburg, Genk and LCRP Oncology Cluster, University of Hasselt, Hasselt, Belgium; #Department of Medical Oncologie, ICO R. Gauducheau, St-Herblain, France; **Department of Oncology, University Hospital S. Maria della misericordia, Udine, Italy; ††Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; ‡‡Northwest Lung Centre, University Hospitals of South Manchester, Manchester, United Kingdom; §§Thoracic Oncology-Pneumology Service, André Renard Clinic, Herstal, Belgium; ¶¶Clinic of Thoracic Surgery, Waldburg-Zeil Clinic, Wangen im Allgäu, Germany; and ‖‖GSK Vaccines, Rixensart, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000653DOI Listing
October 2015

Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?

Curr Pharm Des 2014 ;20(24):3863-74

Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/13816128113196660756DOI Listing
March 2015

Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.

J Thorac Oncol 2015 Feb;10(2):392-6

*Medical Oncology Department, Thoracic Oncology Division, and †Pathology and Laboratory Medicine Department, Pathology Division, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000355DOI Listing
February 2015

Ceritinib in ALK-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Mar;370(13):1189-97

From Massachusetts General Hospital, Boston (A.T.S., J.A.E.); Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Fox Chase Cancer Center, Philadelphia (R.M.); National Cancer Center and Genome Institute of Singapore, Singapore (D.S.W.T.); Vall d'Hebron University, Barcelona (E.F.); University of Washington, Seattle (L.Q.M.C.); University of Colorado, Denver (D.R.C.); University Hospital KU Leuven, Leuven, Belgium (J.V.); Huntsman Cancer Institute, Salt Lake City (S.S.); Istituto Europeo di Oncologia (T.D.P.) and Istituto di Ricovero e Cura a Carattere Scientifico Istituto Clinico Humanitas (A.S.) - both in Milan; Memorial Sloan-Kettering Cancer Center, New York (G.J.R.); Peter MacCallum Cancer Center, Melbourne, VIC, Australia (B.J.S.); Center for Integrated Oncology, University Hospital Cologne, Cologne (J.W.), Thoraxklinik, University of Heidelberg, Translational Lung Research Center Heidelberg, German Center for Lung Research (M.T.), and German Cancer Consortium (M.S.), Heidelberg, and University Duisburg-Essen, Essen (M.S.) - all in Germany; Princess Margaret Cancer Center, Toronto (G.L.); and Novartis Institutes for BioMedical Research, Cambridge, MA (Y.Y.L., M.G., A.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1311107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079055PMC
March 2014

Stem cell transplantation effectively occludes bronchopleural fistula in an animal model.

Ann Thorac Surg 2014 Feb 25;97(2):480-3. Epub 2013 Dec 25.

Department of Health, Animal Science and Public Health, Università degli Studi di Milano, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2013.10.032DOI Listing
February 2014

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung.

Lung Cancer 2013 Sep 27;81(3):440-444. Epub 2013 Jun 27.

Thoracic and Sarcoma Oncology Unit, Division of New Drug Development and Clinical Pharmacology, Medical Oncology Department, European Institute of Oncology, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.05.019DOI Listing
September 2013

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.

Future Oncol 2013 Mar;9(3):327-45

Medical Oncology Unit of Respiratory Tract & Sarcomas, New Drugs Development Division, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.13.6DOI Listing
March 2013

Sarcoma of the breast: outcome and reconstructive options.

Clin Breast Cancer 2012 Dec 11;12(6):438-44. Epub 2012 Oct 11.

Division of Senology, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2012.09.008DOI Listing
December 2012

Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?

Clin Exp Metastasis 2012 Oct 15;29(7):757-73. Epub 2012 Jun 15.

Division of Melanoma and Sarcoma, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-012-9502-4DOI Listing
October 2012

Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.

Crit Rev Oncol Hematol 2012 Sep 25;83(3):432-43. Epub 2012 Feb 25.

Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drugs Development Division, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428110027
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2011.12.005DOI Listing
September 2012

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

Pharmacogenomics 2012 Jul;13(9):1073-86

Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.12.91DOI Listing
July 2012

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

J Clin Oncol 2011 Dec 31;29(34):e819-22. Epub 2011 Oct 31.

Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drugs Development Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.36.2251DOI Listing
December 2011

A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer.

Acta Oncol 2010 May;49(4):480-4

New Drugs Development and Clinical Pharmacology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/02841860903490077DOI Listing
May 2010

Review article: pulmonary sarcomatoid carcinomas: a practical overview.

Int J Surg Pathol 2010 Apr 4;18(2):103-20. Epub 2009 Jan 4.

Division of Pathology and Laboratory Medicine, University of Milan School of Medicine, Milan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1066896908330049DOI Listing
April 2010

Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.

Eur J Cancer 2008 Mar 19;44(4):494-500. Epub 2007 Nov 19.

Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2007.10.001DOI Listing
March 2008

Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases.

Crit Rev Oncol Hematol 2008 Jan 19;65(1):1-7. Epub 2007 Jul 19.

New Drugs Development and Clinical Pharmacology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S104084280700116
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2007.06.003DOI Listing
January 2008

Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.

Breast Cancer Res Treat 2007 Nov 27;106(1):97-103. Epub 2007 Jan 27.

Unit for Medical Care, Division of Medical Oncology, European Institute of Oncology, 20141, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-006-9481-8DOI Listing
November 2007

Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.

Prostate 2007 May;67(6):603-4

Division of Medical Oncology, Clinical Pharmacology and New Drugs Development Unit, European Institute of Oncology and University of Milan School of Medicine, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20530DOI Listing
May 2007

Prognostic role of lymph node involvement in lung metastasectomy.

J Thorac Cardiovasc Surg 2007 Apr 26;133(4):967-72. Epub 2007 Feb 26.

Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2006.09.104DOI Listing
April 2007

Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer.

J Thorac Oncol 2007 Feb;2(2):131-4

Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
February 2007

Erlotinib-induced breast cancer regression.

Ann Pharmacother 2006 Nov 24;40(11):2043-7. Epub 2006 Oct 24.

Medical Care Unit, Department of Medicine, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1345/aph.1H252DOI Listing
November 2006

Primary and recurrent retroperitoneal soft tissue sarcoma: prognostic factors affecting survival.

J Surg Oncol 2006 May;93(6):456-63

Department of General Surgery, European Institute of Oncology, University of Milano, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.20446DOI Listing
May 2006

Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer.

Breast Cancer Res Treat 2005 Aug;92(3):265-72

Division of Medical Oncology, Day Hospital Unit & Unit of Psycho-oncology, Department of Medicine, European Institute of Oncology, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-005-3376-yDOI Listing
August 2005

Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung.

Lung Cancer 2005 May 23;48(2):233-40. Epub 2004 Dec 23.

Thoracic Surgery Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2004.10.018DOI Listing
May 2005

Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study.

Bull Cancer 2004 Sep 1;91(9):E273-7. Epub 2004 Sep 1.

Department of Medical Oncology, Division of Thoracic Surgery and Radiotherapy, European Institute of Oncology, Via Ripamonti, 435, 20141, Milan, Italy.

View Article

Download full-text PDF

Source
September 2004

Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.

Pharmacol Rev 2003 Mar;55(1):57-103

Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/pr.55.1.4DOI Listing
March 2003

Endometrial malignant melanoma rediagnosed as clear-cell "sugar" tumour.

Lancet Oncol 2002 Dec;3(12):764-5

Department of Radiation Oncology, European Institute of Oncology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
December 2002